# The correlation between antibiotic usage and antibiotic resistance: a 3-year retrospective study

**Authors:** Ann Lisa Arulappen, Amer Hayat Khan, Syed Shahzad Hasan, Sabariah Noor Harun, Ting Soo Chow, Mahmood Basil A. Al-Rawi, Wajid Syed

PMC · DOI: 10.3389/fcimb.2025.1608921 · Frontiers in Cellular and Infection Microbiology · 2025-08-01

## TL;DR

This study found a strong positive correlation between antibiotic usage and antibiotic resistance in six hospitals in Penang over three years.

## Contribution

The study provides empirical evidence of a strong correlation between specific antibiotic usage and resistance rates in clinical settings.

## Key findings

- Third-generation cephalosporin usage correlated strongly with extended-spectrum beta-lactamase (ESBL) rates.
- Carbapenem usage correlated strongly with carbapenem-resistant Enterobacterales (CRE) rates.
- Some microorganisms showed significant changes in prevalence and resistance patterns over time.

## Abstract

Multidrug-resistant (MDR) microorganisms have increased all over the world, which is considered a public health threat. The emergence of MDR bacterial pathogens correlates with the increased antibiotic usage. This study aimed to determine the correlation between antibiotic usage and antibiotic resistance within 3 years.

This was a retrospective cross-sectional study reviewing the positive bacterial culture results and the total antibiotic usage in six hospitals in Penang for 3 years from January 2021 to December 2023 through a convenient sampling method.

Every sample type has experienced a significant shift over the years. Most microorganisms from all samples significantly changed in distribution over time, except for Streptococcus pneumoniae, carbapenem-resistant Enterobacterales (CRE) Escherichia coli, and CRE Klebsiella pneumoniae. However, methicillin-resistant Staphylococcus aureus (MRSA), K. pneumoniae, and Pseudomonas aeruginosa showed significant changes in the number of total isolates from blood cultures only in the 3 years. In terms of prevalence, statistically significant differences were observed for most microorganisms from all samples except for S. pneumoniae, CRE E. coli, and CRE K. pneumoniae across the years. P. aeruginosa showed significant prevalence in blood culture over time. Cefoperazone/sulbactam, amoxicillin/clavulanic acid, ceftriaxone, and ceftazidime showed significant changes in susceptibility for K. pneumoniae over time. A statistically significant difference in total antibiotic usage across the 3 years was observed. Regarding the correlation between antibiotic usage and antibiotic resistance, Pearson’s correlation was 0.777 (p = 0.433), which is suggestive of a strong positive correlation between third-generation cephalosporin usage and extended-spectrum beta-lactamase (ESBL), whereas Pearson’s correlation was 0.762 (p = 0.448), which also suggests strong positive correlation between carbapenem usage and CREs.

The correlation between the use of third-generation cephalosporins and ESBL rate, as well as the use of carbapenems and CRE rate, further suggests that controlling certain antibiotic usage could help mitigate the rise in MDR microorganisms.

## Linked entities

- **Chemicals:** amoxicillin/clavulanic acid (PubChem CID 6435924), ceftriaxone (PubChem CID 5479530), ceftazidime (PubChem CID 5481173)
- **Diseases:** Streptococcus pneumoniae infection (MONDO:0005114)
- **Species:** Streptococcus pneumoniae (taxon 1313), Escherichia coli (taxon 562), Klebsiella pneumoniae (taxon 573), Staphylococcus aureus (taxon 1280), Pseudomonas aeruginosa (taxon 287)

## Full-text entities

- **Genes:** Extended-spectrum beta-lactamase [NCBI Gene 13982007]
- **Diseases:** MRSA (MESH:D013203), infectious disease (MESH:D003141), respiratory diseases (MESH:D012140), deaths (MESH:D003643), MDR (MESH:D018088), AMR (MESH:D060467), ESBL (MESH:C579922), COVID-19 (MESH:D000086382), DDD (MESH:D020773), kidney diseases (MESH:D007674), bacterial co-infection (MESH:D060085), Antibiotic (MESH:D004761), Infections (MESH:D007239), bacterial infections (MESH:D001424), digestive diseases (MESH:D004066), diabetes (MESH:D003920), transport injuries (MESH:D014947), urinary tract and bloodstream infections (MESH:D014552), respiratory, intra-abdominal, and urinary tract infections (MESH:D012141), neurological disorders (MESH:D009461)
- **Chemicals:** trimethoprim/sulfamethoxazole (MESH:D015662), carbapenem (MESH:D015780), aminoglycosides (MESH:D000617), imipenem (MESH:D015378), penicillins (MESH:D010406), sulbactam (MESH:D013407), cefepime (MESH:D000077723), cefotaxime (MESH:D002439), ceftazidime (MESH:D002442), piperacillin/tazobactam (MESH:D000077725), amoxicillin/clavulanic acid (MESH:D019980), NDM (MESH:C052821), vancomycin (MESH:D014640), cephalosporin (MESH:D002511), rifampicin (MESH:D012293), ertapenem (MESH:D000077727), Meropenem (MESH:D000077731), beta-lactam (MESH:D047090), cefuroxime (MESH:D002444), cefoperazone (MESH:D002438), fluoroquinolones (MESH:D024841), ceftriaxone (MESH:D002443), ciprofloxacin (MESH:D002939), ampicillin (MESH:D000667), methicillin (MESH:D008712), ampicillin/sulbactam (MESH:C035444), clavulanic acid (MESH:D019818), -generation cephalosporin (-)
- **Species:** Klebsiella pneumoniae (species) [taxon 573], Enterobacterales (order) [taxon 91347], Enterococcus faecium (species) [taxon 1352], Acinetobacter baumannii (species) [taxon 470], Escherichia coli (E. coli, species) [taxon 562], Homo sapiens (human, species) [taxon 9606], Staphylococcus aureus (species) [taxon 1280], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Enterococcus faecalis (species) [taxon 1351], Streptococcus pneumoniae (species) [taxon 1313], Anas platyrhynchos (duck, species) [taxon 8839], Pseudomonas aeruginosa (species) [taxon 287]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12353727/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12353727/full.md

---
Source: https://tomesphere.com/paper/PMC12353727